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The programmed cell death-1 (PD-1)/programmed cell
death-1 ligand (PD-L1) pathway has been shown to play
a pivotal role in tumor evasion. Inhibition of PD-1 and its
ligand PD-L1 using an immune checkpoint inhibitor has
emerged as a promising immunotherapy for the treat-
ment of various types of cancer. The expression of PD-L1
in tumor cells and tumor-infiltrating lymphocytes (TILs)
has been shown to be correlated with improved efficacy
of antibodies against PD-1 or PD-L1. Moreover, the den-
sity of CD8+ TILs has been shown to be correlated with
the response to immunotherapy. In this study, we exam-
ined the expression of PD-L1, CD25, PD-1, FoxP3, CD4,
CD8, and EpCAM in 42 peripheral blood samples and
fresh tumor specimens using multiparametric flow cyto-
metry. Our results showed that the percentages of PD-
L1-expressing CD25+ CD4+ T cells were significantly
higher in TILs than in peripheral blood lymphocytes
(PBLs; TILs: mean, 48.6%; range, 23.6–81.5% versus
PBLs: mean, 35.4%; range, 16.8–64.3%; P < 0.001). The
density of CD25+ PD-L1+ CD4+ TILs positively corre-
lated with that of PD-1+ CD8+ TILs but negatively corre-
lated with interferon (IFN)-g+ and tumor necrosis factor
(TNF)-b+ CD8+ TILs. However, the high ratio of CD8+
TILs to that of CD25+ PD-L1+ CD4+ TILs or to EpCAM+
tumor cells were associated with high percentages of
IFN-g+ and TNF-b+ CD8+ TILs. Moreover, inhibition of
PD-L1 and PD-1 decreased the density of CD25+ PD-L1+
CD4+ cells and PD-1+ CD8+ TILs but increased the per-
centage of IFN-g+ and TNF-b+ CD8+ cells. High ratios of
CD8+ TILs to CD25+ PD-L1+ CD4+ TILs or to EpCAM+
tumor cells enhanced the activity of tumor-specific CD8+
T cells after PD-1/PD-L1 blockade therapy. Taken
together, our results highlighted the importance of
CD25+ PD-L1+ CD4+ TILs in mediating the tumor
microenvironment immune response. Our findings also
indicated that high ratios of CD8+ TILs to CD25+ PD-
L1+ CD4+ TILs or to EpCAM+ tumor cells in patients
may be more effective after PD-1/PD-L1 blockade ther-
apy. Thus, the variable density of CD8+ and CD25+
PD-L1+ CD4+ T cells within the tumor microenviron-
ment caused differential responses to PD-1/PD-L1
blockade.
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Figure 2 Correlation between the clinicopathologic characteristics and PD-1+CD8 TIL or PD-L1+CD4 TIL in 42 lung cancer patients.
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